Profusa Raises Conversion Floor to $0.35, Eliminates Amortization on Notes
Profusa restructured its Senior Secured Convertible Notes by eliminating mandatory amortization, extending maturity to 18 months, raising the conversion floor to $0.35 from $0.10, and boosting mandatory ELOC payments from 33% to 50%. CFO Fred Knechtel said the amendments reduce dilution and enhance repayment flexibility for its balance sheet.
1. Expansion of European Commercial Footprint
Profusa has secured a new distribution agreement with MedSell to commercialize its Lumee™ Oxygen tissue monitoring device in France, complementing existing partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom and Scandinavia. Together, these agreements position Profusa to address roughly 200,000 annual cases of critical limb ischemia (CLI) across the European Union. The French agreement also builds on a key opinion leader collaboration with Professor Yann Gouëffic at Groupe Hospitalier Paris Saint Joseph, who manages approximately 8% of all CLTI cases in France and will integrate Lumee monitoring into both clinical practice and home‐based studies.
2. Revenue Projections Driven by European Launch
Profusa projects generating between $0.5 million and $2 million in revenue during 2026 as the company begins European commercialization in the second quarter, ramping to $9 million–$13 million in 2027 when U.S. commercialization is targeted to commence. Over the longer term, management aims to reach annual revenue of $200 million–$250 million by 2030, driven by broader adoption of its continuous‐monitoring biosensor platform in vascular, wound care and chronic disease management settings.
3. Balance Sheet Recapitalization and Reduced Dilution
On December 30, Profusa announced the restructuring of its Senior Secured Convertible Notes to improve financial flexibility and minimize shareholder dilution. Key amendments include elimination of mandatory amortization payments scheduled for early 2026, extension of final maturity to 18 months post-issuance, and an increase in the conversion floor price to $0.35 from $0.10. Additionally, mandatory Equity Line Of Credit (ELOC) payments will rise from 33% to 50% for shares issued under future Form S-1 registration statements, reflecting management’s commitment to strengthen the balance sheet and enhance enterprise value.
4. Strategic Focus on Clinical Validation and Cost Reduction
Profusa’s leadership emphasizes ongoing clinical validation of Lumee Oxygen tissue monitoring, highlighted by presentations of U.S. trial data at Paris Vascular Insights and the Leipzig Interventional Course. The company is prioritizing initiatives to expand partnerships, accelerate inventory build for the 2026 European launch and develop protocols for at-home monitoring. Management believes these efforts will improve patient outcomes, reduce healthcare costs associated with chronic wounds and ischemic limb management, and support the path to sustainable profitability.